Dr. Maude St-Onge completed her medical studies at Université de Montréal in 2006, specialized in Emergency Medicine at Laval University in 2011, and in Critical Care at the University of Toronto in 2013, and in Clinical Pharmacology and Toxicology at the University of Toronto, in 2016. Dr. St-Onge obtained a Master’s Degree in Public Health in 2004 and a Ph.D. in Medical Sciences in 2015 from the University of Toronto under the supervision of renowned scientists in the field of acute care, such as Dr. Laurie Morrison (scientist in emergency medicine), Dr. David Juurlink (clinician-scientist in toxicology) and Dr. Gorden Rubenfeld (clinician-scientist in critical care medicine). Her Ph.D. aimed at developing international recommendations for the management of calcium channel blocker poisoning and included a systematic review, a retrospective study, an economic study, a survey, and a Delphi.
Since July of 2015, Dr. Maude St-Onge has been the medical director of the Centre antipoison du Québec, works as an intensivist clinician-scientist at the CHU de Québec and as an assistant professor for the Department of Family Medicine and Emergency Medicine, as well as the Laval University Department of Anesthesiology and Critical Care Medicine. Scientist awarded by the FRQS working at the CHU de Québec – Laval University research center for the Population Health and Optimal Health Practice Research (Trauma – Emergency – Critical Care), Dr. St-Onge’s research interests concern acute care toxicology. She is currently studying the factors influencing adherence to the recommendations she developed during her Ph.D. (qualitative study, matched crossover study), evaluating the risks and benefits related to the administration of activated charcoal to poisoned patients (activated CHARcoal in Poisoned Patients – CHARPP: systematic review, retrospective study, survey, validation of a clinical score, pilot study, clinical trial), and working to better understand the continuum of care provided to Indigenous poisoned patients (CARe for Indigenous Poisoned Patients – CARIPP: scoping review, retrospective study, qualitative study). Indeed, activated charcoal is the most often recommended intervention by poison centres and the Indigenous population is the most affected by poisonings.
Latest news
- Mama-sika, Kamil El BakrMaster studentkamil-el-bakr.mama-sika.1@ulaval.ca
Frequency of Screening and Spontaneous Breathing Trial Techniques: A Randomized Clinical Trial
Journal ArticleJAMA, 2024.
Continuous naloxone infusion for the treatment of guanfacine toxicity in a 2-year-old male
Journal ArticleCJEM, 2024.
Liberal or Restrictive Transfusion Strategy in Patients with Traumatic Brain Injury
Journal ArticleN Engl J Med, 391 (8), 2024.
Antidote use for cardiac arrest or hemodynamic instability due to cardiac glycoside poisoning: A narrative review
Journal ArticleResusc Plus, 19 , 2024.
Stress Ulcer Prophylaxis during Invasive Mechanical Ventilation
Journal ArticleN Engl J Med, 391 (1), 2024.
Clinical Outcomes of Indigenous Versus Non-Indigenous Patients: A Multicenter Retrospective Cohort Study in the Province of Quebec
Journal ArticleJ Prim Care Community Health, 14 , 2023.
Effect of Taste Additives on the Palatability of Activated Charcoal: a Systematic Review
Journal ArticleJ Med Toxicol, 19 (3), 2023.
2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care
Journal ArticleCirculation, 148 (16), 2023.
IV Vitamin C in Adults With Sepsis: A Bayesian Reanalysis of a Randomized Controlled Trial
Journal ArticleCrit Care Med, 51 (8), 2023.
Intravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials
Journal ArticleJAMA, 330 (18), 2023.
Active projects
- BETTER-ED: Expanding the Patient-Oriented Research Capacity of the Canadian Emergency Department Rapid Response Network, from 2024-01-01 to 2024-12-31
- Titre du projet : CHARPP, from 2023-09-22 to 2025-09-30
Recently finished projects
- activated CHARcoal in Poisoned Patients (CHARPP): a pilot Randomized Controlled Trial, from 2023-04-01 to 2024-03-31
- Utilisation du charbon activé chez les patients intoxiqués (CHARPP - Use of activated CHARcoal in Poisoned Patients), from 2016-07-01 to 2023-06-30